A carregar...
Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung Cancer
[Image: see text] Epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (KRAS) oncogenic mutations are leading causes for lung cancer. Extensive drug discovery efforts targeting EGFR have led to the discovery and FDA approval of both reversible and covalent inhibitor...
Na minha lista:
| Publicado no: | ACS Med Chem Lett |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Chemical
Society
2018
|
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6142066/ https://ncbi.nlm.nih.gov/pubmed/30258528 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.8b00311 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|